Pharmacy Management Drug Policy
|
|
- Jodie Linette Hensley
- 7 years ago
- Views:
Transcription
1 Page 1 of 5 Description: Pulmonary arterial hypertension (PAH) is characterized by sustained elevation of pulmonary artery pressure. The condition is uncommon but is associated with a high mortality rate. Some causes of pulmonary hypertension include congenital heart defects, connective tissue disease, HIV infection, blood clots, liver disease, and medication (ex. Fen-phen). The disease can also have an unknown cause (primary pulmonary hypertension, PPH). The most common symptoms caused by PAH are unusual fatigue, SOB, chest pain, fainting, and peripheral edema. Careful invasive assessment of pulmonary hemodynamics is critical in the evaluation of any patient with suspected PAH. All patients that are suspected of having PAH after non-invasive evaluation (chest X-ray or echocardiogram) should undergo right heart catheterization (RHC) prior to initiating therapy. RHC can be performed safely even in patients with severe pulmonary hypertension and right heart failure. Treatment goals include improvement in patient symptoms such as dyspnea and exercise endurance, lowering pulmonary artery pressure, prevent progression of disease and improve survival. Medical management for PAH includes oral calcium-channel blockers, anticoagulants, oxygen therapy, endothelial-receptor antagonists (bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and prostacyclins (iloprost, treprostinil, epoprostonol) and the newer class of sgc inhibitors (riociguat). Lung and heart transplants have been performed in those patients that are refractory to medical management. Class 1 Class 2 Class 3 Class 4 New York Heart Association Functional Classification Ordinary physical activity does not cause symptoms Comfortable at rest, ordinary physical activity causes symptoms Comfortable at rest, less than ordinary activity (ADLs) causes symptoms Symptoms at rest This policy is applicable to the following drugs that are FDA approved for the treatment of PAH Adcirca Adempas Flolan (epoprostenol) Letairis Orenitram Opsumit Remodulin Revatio (sildenafil) Tracleer Veletri Ventavis
2 Page 2 of 5 PAH Policy Criteria: 1. The patient must have a diagnosis of Pulmonary Arterial Hypertension which has been confirmed by a right heart catheterization. 2. The right heart catheterization must demonstrate the following: Mean pulmonary artery pressure (PAP) of to 25 mmhg at rest AND Pulmonary capillary wedge pressure to 15 mm Hg at rest 3. Patient must be followed by and drug therapy prescribed by a cardiologist or pulmonologist. 4. Adcirca and generic sildenafil will be approved as initial treatment for anyone with a confirmed diagnosis of PAH. 5. New starts for Letairis, Tracleer, Revatio or Opsumit will require a trial of generic sildenafil or Adcirca prior to approval of one of these agents. 6. New starts for Adempas for a diagnosis of PAH will require a trial of sildenafil or Adcirca and an endothelin receptor antagonist (Letairis, Tracleer or Opsumit) prior to approval. Past treatment with a prostacyclin (Flolan, Veletri, Tyvaso, Remodulin or Ventavis) will also be taken in to consideration if used as one of two previous therapies. 7. New starts for Orenitram will require a trial of sildenafil or Adcirca and an endothelin receptor antagonist (Letairis, Tracleer or Opsumit) prior to approval. Past treatment with a prostacyclin (Flolan, Veletri, Tyvaso, Remodulin or Ventavis) will also be taken in to consideration if used as one of two previous therapies. 8. New starts for Flolan (epoprostenol), Remodulin, Tyvaso, Veltri, and Ventavis will require a trial of sildenafil or Adcirca and an endothelin receptor antagonist (Letairis, Tracleer or Opsumit) prior to approval for lower risk individuals (typically WHO Class II and III). a. Patients at high risk (WHO Class IV) may require continuous treatment with IV prostacyclin as initial therapy. 9. Combination therapy has been studied for the treatment of PAH. The goal of combination therapy should be to maximize efficacy, while minimizing toxicity. For individuals who have inadequate response, combination therapy (with drugs with different mechanisms of action) can be considered. Combination therapy should only be attempted by those with the expertise to monitor such high risk individuals. Adempas specific criteria: 1. Can be used for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) and have: a. Recurrent or persistent disease after surgical disease OR b. Inoperable disease determined by V/Q scan and/or pulmonary angiography Exclusion Criteria:
3 Page 3 of 5 1. Conditions considered investigational will not be covered. Conditions considered investigational due to lack of peer-reviewed literature for which efficacy or safety data is not yet available include, but are not limited to: Ischemic vascular diseases Congestive heart failure Chronic obstructive pulmonary disease 2. The use of Revatio or Adcirca and nitrates concurrently is contraindicated and therefore will not be covered. 3. Revatio (Sildenafil 20mg) and Adcirca will not be authorized for a diagnosis of erectile dysfunction as there are FDA approved medications for this diagnosis. Policy Guidelines: 1. Prior authorization is contract dependent. 2. Patient must have a right heart catheterization to diagnose Pulmonary Arterial Hypertension 3. Patient must be followed by a cardiologist or pulmonologist 4. Adcirca, Adempas, Revatio (sildenafil), Opsumit, Orenitram, and Tracleer are covered under the pharmacy benefit. 5. Ventavis is covered under the medical benefit to coordinate care with the necessary supplies. Proper verification (based on Part B vs D determination) is necessary for Medicare requests. 6. Tyvaso is self-administered and therefore should be processed under the pharmacy benefit. Proper verification (based on Part B vs D determination) is necessary for Medicare requests. 7. Remodulin, Flolan (epoprostenol) and Veletri are covered under the medical benefit. 8. Sildenafil (Revatio) has been shown to be safe and effective up to a maximum dose of 80mg three times a day for the treatment of PAH. Doses above FDA approval will require documentation of a trial of the lower FDA approved dose which was shown to be ineffective. 9. Tadalafil (Adcirca) has been shown to be safe and effective up to a maximum dose of 40mg once a day. Doses above FDA approval will require documentation of a trial of the lower FDA approved dose which was shown to be ineffective. 10. Maximum dosing of bosentan (Tracleer) is 125mg twice a day. 11. Maximum dosing of ambrisentan (Letairis) is 10mg once a day. 12. Maximum dosing of riociguat (Adempas) is 2.5mg three times a day. 13. Maximum dosing of macitentan (Opsumit) is 10mg once a day. 14. There is no FDA approved maximum dose of oral treprostinil Orenitram, but the maximum dose allowed within the clinical trials was 16mg twice a day. 15. Surgery is the only definitive therapy for chronic thromboembolic pulmonary hypertension (CTEPH), with pulmonary thromboendarterectomy being the surgical procedure of choice
4 Page 4 of 5 CODES: Eligibility for reimbursement is based upon the benefits set forth in the member s subscriber contract. CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY. Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates. HCPCS: J1325 Flolan, Veletri (Esoprostenol) J3285 Remodulin (Treprostinil) References: 1. Badesch D, et al. Medical therapy for pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines. CHEST 2004; 126:35S-57S. 2. Sitbon O, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: Sitbon O, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: Opitz CF, et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: Barst RJ, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Eng J Med 1996; 334: Rich S, et al. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: Shapiro SM, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: McLaughlin VV, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 40: Simonneau G, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: Hoeper MM, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Eng J Med 2000; 342: Channick RN, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358:
5 Page 5 of Michelakis E, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J Dec;28(6): Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48(8): Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest Sep;132(3): Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as addon therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48(7): Flolan package insert, GSK. September Tracleer package insert, Actelion Inc. March Remodulin package insert, Baxter. November Ventavis package insert, CoTherix Inc. December Revatio package insert, Pfizer, June Letairis package insert, Gilead Sciences, Inc. June Adcirca package insert, Eli Lilly & Company marketed by United Therapeutics May McLaughlin VV et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. J of American College of Cardiology. 53(17) Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2009:30:
PULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan
More informationOVERVIEW FDA-APPROVED INDICATIONS
Tufts Health Together Tufts Health Direct Pharmacy Medical Necessity Guidelines Pulmonary Hypertension Effective: December 9, 2014 Clinical documentation and prior authorization required Not covered Pharmacy
More informationPharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications
Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Pulmonary Arterial Hypertensive (PAH) agents Rx.01.83 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More information*Documentation of pretreatment results from right heart catheterization and PEA required, as applicable
DRUG POLICY BENEFIT APPLICATION Pulmonary Arterial Hypertension Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationPulmonary Artery Hypertension
Pulmonary Artery Hypertension Janet M. Pinson, RN, MSN, ACNP Maureen P. Flattery, RN, MS, ANP Virginia Commonwealth University Health System Richmond, VA Pulmonary artery hypertension (PAH) is defined
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil citrate 20mg tablets (Revatio ) No. (235/06) Pfizer New indication 6 January 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationCLINICAL POLICY Department: Medical Management Document Name: Pulmonary Arterial Hypertension Therapies
Page: 1 of 15 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationCorporate Medical Policy
Corporate Medical Policy Pulmonary Hypertension, Drug Management File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pulmonary_hypertension_drug_management 06/1998 3/2015 3/2016 3/2015
More informationTherapeutic Class Overview Pulmonary Arterial Hypertension Agents
Therapeutic Class Overview Pulmonary Arterial Hypertension Agents Therapeutic Class Overview/Summary: The oral pulmonary hypertension agents are Food Drug Administration (FDA)-approved for the treatment
More informationRiociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
More informationPULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana
PULMONARY HYPERTENSION Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana What is Pulmonary Hypertension? What is normal? Pulmonary artery systolic pressure
More informationAdvanced Therapies for Pharmacological Treatment of Pulmonary Hypertension
Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationRecently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension
DISEASE MANAGEMENT Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension Treatment of pulmonary arterial hypertension (PAH) Class I. PAH without
More informationCopyright 2012 Oregon State University. All Rights Reserved
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPulmonary Arterial Hypertension: Review and Updates. Is it Primary vs Secondary Pulmonary Hypertension? No!! Dated Nomenclature. Veronica Franco, MD
Pulmonary Arterial Hypertension: Review and Updates Veronica Franco, MD Section of Pulmonary Hypertension Section of Heart Failure and Transplantation Ohio State University Is it Primary vs Secondary Pulmonary
More informationTarget therapies for the treatment of pulmonary arterial hypertension in Adults
Paper K2 National Specialised Commissioning Group Commissioning Policy Target therapies for the treatment of pulmonary arterial hypertension in Adults POLICY PUBLISHED: 1 JULY 2008 POLICY REVISED: 14 JANUARY
More informationPAH has an incidence
Pulmonary Arterial Hypertension: A Serious Problem Pulmonary arterial hypertension (PAH) is a serious disease with significant morbidity and mortality and no cure. In this article, Dr. Porhownik and Dr.
More informationClinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II. April 2013. Reference : NHSCB/A11/P/a
Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II April 2013 Reference : NHS Commissioning Board Clinical Commissioning Policy: Amendment to National Policy
More informationCADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION RIOCIGUAT (Adempas Bayer HealthCare Inc.) Indication: Pulmonary Arterial Hypertension Recommendation: The CADTH Canadian Drug Expert Review
More information2. Background This drug had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission
More informationChronic Thromboembolic Disease. Chronic Thromboembolic Disease Definition. Diagnosis Prevention Treatment Surgical Nonsurgical
Chronic Thromboembolic Disease Diagnosis Prevention Treatment Surgical Nonsurgical Chronic Thromboembolic Disease Definition Pulmonary Hypertension due to chronic thromboembolism 6 months post acute PE:
More informationThe Global Alliance against Chronic Respiratory Diseases
The Global Alliance against Chronic Respiratory Diseases Pulmonary hypertension Dr Marc Humbert What is the burden of pulmonary hypertension? The true burden of pulmonary hypertension is currently unknown
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents ELIGIBILITY CRITERIA FOR INITIATION OF PULMONARY ARTERIAL HYPERTENSION THERAPY... 2 Initial Application for Funding of Pulmonary
More informationPulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled Therapeutic Class Review (TCR) March 30, 2015
Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled Therapeutic Class Review (TCR) March 30, 2015 No part of this publication may be reproduced or transmitted in any form or by any means, electronic
More informationHope in 2011 Clinical Advances Where is the road taking us?
Hope in 2011 Clinical Advances Where is the road taking us? Richard Channick, MD Arlene Schiro, NP Disclosures Arlene Schiro no relevant financial and/or commercial relationships to disclose Hope is like
More informationPulmonary Arterial Hypertension (PAH) Agents 12/01/2009
Pulmonary Arterial Hypertension (PAH) Agents 12/01/2009 Copyright 2006-2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this
More informationMeta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension Bing He, BSc;
More informationP pulmonary Hypertension and Its Importance to the Body
Cardiol Clin 22 (2004) 441 452 Diagnosis and treatment of pulmonary arterial hypertension Richard Channick, MD a, *, Timothy L. Williamson, MD b a Division of Pulmonary and Critical Care, University of
More informationCADTH Therapeutic Review Report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review Report March 2015 Drugs for Pulmonary Arterial Hypertension:
More informationPulmonary Arterial Hypertension. Matt Hegewald, MD FCCP St Charles Medical Center Intermountain Medical Center University of Utah
Pulmonary Arterial Hypertension Matt Hegewald, MD FCCP St Charles Medical Center Intermountain Medical Center University of Utah Intermountain Pulmonary Arterial Hypertension Program Outline Causes of
More informationWe can learn a lot from you...
Educational program by Material endorsed by We can learn a lot from you... When it comes to pulmonary arterial hypertension (PAH), the members of your specialist healthcare team are experts on the best
More informationPulmonary Arterial Hypertension: Assessment of disease s severity
Pulmonary Arterial Hypertension: Assessment of disease s severity Carmine Dario Vizza Dept. Cardiovascular and Respiratory Diseases La Sapienza University of Rome e-mail : dario.vizza@uniroma1.it Pulmonary
More informationPulmonary Hypertension in Sickle Cell Disease. Jorge Ramos Hematology Fellows Conference June 28, 2013
Pulmonary Hypertension in Sickle Cell Disease Jorge Ramos Hematology Fellows Conference June 28, 2013 Patient Presentation 28F with SCD, genotype SS. Presented to UWMC ER with 1 month progressive DOE and
More informationPAH. Salman Bin AbdulAziz University College Of Pharmacy 22/01/35
Salman Bin AbdulAziz University College Of Pharmacy PAH Therapeutics II PHCL 430 Ahmed A AlAmer PharmD R.W. is a 38-year-old obese woman who presents with increasing symptoms of fatigue and shortness of
More informationEvidence briefing on drug treatments for functional class II pulmonary hypertension
Evidence briefing on drug treatments for functional class II pulmonary hypertension The North of England Specialised Commissioning Group is the lead organisation charged with commissioning targeted therapies
More informationACTELION S MARKETED PRODUCTS
ACTELION S Actelion has over 1,000 highly experienced sales, marketing and medical professionals with a proven track record in both specialty and GP markets. The company has over 30 operative affiliates
More informationAcknowledgements. PAH in Children: Natural History. The Sildenafil Saga
The Sildenafil Saga David L. Wessel, MD Executive Vice President Chief Medical Officer Ikaria Distinguished Professor of Critical Care Children s National Medical Center Washington, DC, USA Acknowledgements
More informationPulmonary Arterial Hypertension
Chapter 27 Pulmonary Arterial Hypertension Gandharba Ray, L Ravi Kumar INTRODUCTION ABSTRACT Pulmonary arterial hypertension (PAH) is a syndrome resulting from decreased flow of blood in the pulmonary
More informationPulmonary Arterial Hypertension Special Issues and Current Therapeutic Approaches: Part Two
The online version of this article, along with access to discussion threads on NATF s eforum, is available at: www.natfonline.org/ethrombosis.php (January, 2010) Pulmonary Arterial Hypertension Special
More informationPulmonary arterial hypertension (PAH) is a
Eur Respir Rev 2010; 19: 118, 279 287 DOI: 10.1183/09059180.00008010 CopyrightßERS 2010 REVIEW Management of severe pulmonary arterial hypertension J-L. Vachiéry* and G. Simonneau # ABSTRACT: Pulmonary
More informationStatement on Disability: Pulmonary Hypertension
Statement on Disability: Pulmonary Hypertension Ronald J. Oudiz, MD and Robyn J. Barst, MD on behalf of Pulmonary Hypertension Association The Scientific Leadership Council of the Pulmonary Hypertension
More informationIdiopathic Pulmonary Fibrosis (IPF) Research
Idiopathic Pulmonary Fibrosis (IPF): Why Early Referral is Critical Even if Your Patient is Not Eligible for a Clinical Trial Idiopathic Pulmonary Fibrosis (IPF) Research Management of IPF requires a confident
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationPAH: Standard of Care
PAH: Standard of Care Nazzareno Galiè Istituto di Cardiologia Università di Bologna nazzareno.galie@unibo.it TF 7 Therapy Standard of Care Questions A. Do we have additional information on the role of
More informationAgenda. Medicare Overview Medicare Part B Drug Coverage Medicare Part D: How to Find and Compare Medicare Part D Plans Summary Provider Contacts
2 Medicare Part D Agenda Medicare Overview Medicare Part B Drug Coverage Medicare Part D: Background Benefits of Medicare Part D Enrollment Coverage Specialty Medications Part D Costs How to Find and Compare
More informationA Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension
A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
More informationNon-Invasive Risk Predictors in (Children with) Pulmonary Hypertension
Ideal risk prognosticator Easy to acquire Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Safe -- Non-invasive Robust Gerhard-Paul Diller Astrid Lammers Division of Adult Congenital
More informationBosentan in Pulmonary Arterial Hypertension Secondary to Scleroderma
Bosentan in Pulmonary Arterial Hypertension Secondary to Scleroderma AMIT JOGLEKAR, FAUSAN S. TSAI, DEBORAH A. McCLOSKEY, JULIANNE E. WILSON, JAMES R. SEIBOLD, and DAVID J. RILEY ABSTRACT. Objective. To
More informationPAH in. Registry to Evaluate Early and Long-Term PAH Disease Management
PAH in Registry to Evaluate Early and Long-Term PAH Disease Management Ioana R. Preston, MD Co-Director, Pulmonary Hypertension Center Tufts Medical Center, Boston, MA Background What is REVEAL? Multi-center,
More informationMedicare C/D Medical Coverage Policy
Medicare C/D Medical Coverage Policy Oxygen and Oxygen Supplements Origination: April 10, 1992 Review Date: July 15, 2015 Next Review: July, 2017 DESCRIPTION OF PROCEDURE OR SERVICE USP Oxygen is a gaseous
More informationFunctional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry
CHEST Original Research PULMONARY VASCULAR DISEASE Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry Robyn J. Barst, MD ;
More informationLiver Function Essay
Liver Function Essay Name: Quindoline Ntui Date: April 20, 2009 Professor: Dr. Danil Hammoudi Class: Anatomy and Physiology 2 Liver function The human body consist of many highly organize part working
More informationResearch Review EDUCATIONAL SERIES. Pulmonary Arterial Hypertension
Research Review EDUCATIONAL SERIES About the Reviewers Dr Ken Whyte is a Respiratory Physician at Auckland DHB Respiratory Services and Honorary Associate Professor of Medicine at the University of Auckland.
More informationShe was 39 years old, gravida 4, para 2. She had an Idiopathic Pulmonary. Arterial Hypertension (PAH) revealed during pregnancy by a New York Heart
Case #1 (year 1992): She was 39 years old, gravida 4, para 2. She had an Idiopathic Pulmonary Arterial Hypertension (PAH) revealed during pregnancy by a New York Heart Association (NYHA) functional class
More informationMedicare C/D Medical Coverage Policy
Nebulizer Medications Origination: June 17, 2009 Review Date: October 21, 2015 Next Review: October, 2017 Medicare C/D Medical Coverage Policy DESCRIPTION Nebulizer medications are used to prevent and
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationDepartment of Surgery
What is emphysema? 2004 Regents of the University of Michigan Emphysema is a chronic disease of the lungs characterized by thinning and overexpansion of the lung-like blisters (bullae) in the lung tissue.
More informationDiagnosis and Management of Pulmonary Arterial Hypertension: Implications for Respiratory Care
Diagnosis and Management of Pulmonary Arterial Hypertension: Implications for Respiratory Care Deborah Jo Levine MD Introduction Definition Normal Physiology Pathophysiology Pathogenesis Classification
More informationType II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationINTRODUCTION TO EECP THERAPY
INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationSector Analysis February 4, 2016
Sector Analysis Analysis of Orphan Drug Market There is significant interest among drug makers and investors alike to focus on the development of products for orphan indications. The reason is these drugs
More informationInpatient Heart Failure Management: Risks & Benefits
Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationTomas Pulido, Carla Murillo, Paulina Ramírez-Neria, Viridiana Hurtado, Paola de la Garza, Sandra Astorga, María Teresa Miranda and Julio Sandoval
Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management of Pulmonary Arterial Hypertension with Sitaxentan
More informationSTUDY DESCRIPTION Background information, study purpose and study rationale
Sylvana M. Hidalgo, MD Originating Department: Pediatric Cardiology Submitting to: Medical Center Title: Single-Center Description of Clinical Presentation of Pulmonary Hypertension in Patients Also Diagnosed
More informationSevere pulmonary arterial hypertension: treatment options and the bridge to transplantation
REVIEW PULMONARY ARTERIAL HYPERTENSION Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation Paul Corris 1 and Bruno Degano 2 Affiliations: 1 Institute of Cellular
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationPulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) Contents 1. Introduction 3 2. What is PAH? 4 3. Classification of PAH 5 4. How is PAH severity classified? 7 5. How common is PAH? 7 6. Why does PAH develop? 8 7.
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More information24. HIV-associated Pulmonary Hypertension
24. HIV-associated Pulmonary Hypertension Georg Friese, Mirko Steinmüller and Ardeschir Ghofrani Etiology, pathogenesis, classification 629 Pulmonary hypertension is a severe life-limiting disease, often
More informationADVANCING KNOWLEDGE. HARNESSING OPPORTUNITY.
ANNUAL REPORT 2012 ADVANCING KNOWLEDGE. HARNESSING OPPORTUNITY. DELIVERING ON OUR STRATEGY. ACTELION TODAY Actelion is a biopharmaceutical company with four products on the market. We are proud of our
More informationCARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
More informationAdvanced Heart Failure & Transplantation Fellowship Program
Advanced Heart Failure & Transplantation Fellowship Program Curriculum I. Patient Care When on the inpatient Heart Failure and Transplant Cardiology service, the cardiology fellow will hold primary responsibility
More informationRiociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
Eur Respir J 2010; 36: 792 799 DOI: 10.1183/09031936.00182909 CopyrightßERS 2010 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study H.A. Ghofrani*,++,
More informationComplications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
Journal of the American College of Cardiology Vol. 48, No. 12, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.07.061
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationCauses and Circumstances of Death in Pulmonary Arterial Hypertension
Causes and Circumstances of Death in Pulmonary Arterial Hypertension Adriano R. Tonelli 1, Vineesha Arelli 1, Omar A. Minai 1, Jennie Newman 1, Nancy Bair 1, Gustavo A. Heresi 1, and Raed A. Dweik 1 1
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationCARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014 Participating Faculty Hector O. Ventura, MD, FACC Section Head, Cardiomyopathy and
More informationCHF: In the trenches. David K. Orth MS RN CNS PHN UCSF, San Francisco, CA, USA
CHF: In the trenches David K. Orth MS RN CNS PHN UCSF, San Francisco, CA, USA No conflicts of interest to disclose Disclosures Objectives Recognize significance of CHF in our patient population Differentiate
More informationPerioperative management solutions for Pulmonary Hypertension. An update and review. Nathaen Weitzel MD
Pulmonary Hypertension (PH) creates a significant challenge for the anesthesiologist, placing patients for surgery in a high risk category. In addition to the elevated intraoperative risk, the limited
More informationFREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationUW MEDICINE PATIENT EDUCATION. Aortic Stenosis. What is heart valve disease? What is aortic stenosis?
UW MEDICINE PATIENT EDUCATION Aortic Stenosis Causes, symptoms, diagnosis, and treatment This handout describes aortic stenosis, a narrowing of the aortic valve in your heart. It also explains how this
More informationCardiopulmonary Exercise Stress Test (CPET) Archived Medical Policy
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationRecommendations: Other Supportive Therapy of Severe Sepsis*
Recommendations: Other Supportive Therapy of Severe Sepsis* K. Blood Product Administration 1. Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial
More informationPulmonal hypertensjon. Arne K. Andreassen Kardiologisk avdeling Oslo Universitetssykehus Rikshospitalet
Pulmonal hypertensjon Arne K. Andreassen Kardiologisk avdeling Oslo Universitetssykehus Rikshospitalet Clinical classification of pulmonary hypertension 1. Pulmonary arterial hypertension (PAH) 2. Pulmonary
More informationThe efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension
(29) 32, 911 915 & 29 The Japanese Society of Hypertension All rights reserved 916-9636/9 $32. www.nature.com/hr ORIGINAL ARTICLE The efficacy and safety of sildenafil in Chinese patients with pulmonary
More informationCIALIS (See-AL-iss) (tadalafil) tablets
1 Patient Information CIALIS (See-AL-iss) (tadalafil) tablets Read this important information before you start taking CIALIS and each time you get a refill. There may be new information. You may also find
More informationInvestor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
More informationTreatment of cardiogenic shock
ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria
More informationGuidelines for diagnosis and management of acute pulmonary embolism
Guidelines for diagnosis and management of acute pulmonary embolism By Dr. Ahmed Zaghloul M.D. Anesthesia & Critical Care 2014 Predisposing factors for VTE Predisposing factor Strong predisposing factors
More information